With more than 4,000 cell and gene therapies (CGTs) in development, plan sponsors should not be ignoring or underestimating the potential impact of these agents, not only on their beneficiaries’ health but also on their own bottom lines. A recent report by Pharmaceutical Strategies Group (PSG), an EPIC company, found that some improvement is needed in this area.
Sponsored by Prescryptive Health and published June 11, “2024 Trends in Drug Benefit Design Report” examines trends among traditional — or nonspecialty — drug benefits, as well as gene therapies.